Investigating the effects of different types of Bullous Pemphigoid on treatment and outcomes
A Retrospective Study of the Effects of Different Pathologic Phenotypes of Bullous Pemphigoid on Clinical Management and Prognosis
This study looks at how different types of Bullous Pemphigoid affect treatment choices and patient outcomes for people who have been hospitalized for this skin condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 318 (estimated) |
| Ages | 0 Years to 100 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06213909 on ClinicalTrials.gov |
What this trial studies
This observational study examines the impact of various sub-pathologic phenotypes of Bullous Pemphigoid (BP) on clinical management and prognosis. It utilizes a retrospective epidemiologic approach, analyzing health data from patients first hospitalized in the Department of Dermatology at Xijing Hospital. The study collects demographic information, medical history, clinical manifestations, and histopathologic features to understand how these factors influence treatment decisions and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with Bullous Pemphigoid who were first hospitalized at Xijing Hospital and have complete skin histopathology information.
Not a fit: Patients who have received systemic glucocorticoids, immunosuppressants, biologics, or other drug therapies within the past month may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic understanding for patients with Bullous Pemphigoid.
How similar studies have performed: While this study focuses on a specific retrospective analysis, similar studies have shown that understanding the heterogeneity of autoimmune diseases can lead to better management and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital * (2) Age 0-100 years old, gender is not limited. * (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests. * (4) Complete skin histopathology information Exclusion Criteria: * (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital. * (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.
Where this trial is running
Xi'an, Shaanxi
- Xijing Hospital — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Principal investigator: Gang Wang, Phd — Dermatology Department of Xijing Hospital
- Study coordinator: Shuai Shao, Phd
- Email: 857746654@qq.com
- Phone: +862984775401
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.